BRD4 ligand-Linker Conjugate 1 (TFA)

• UNSPSC Description:

  BRD4 ligand-Linker Conjugate 1 TFA (compound 106-1) is a target protein ligand-linker conjugate that can be used in the synthesis of PROTACs[1][2].

• Target Antigen:

  Target Protein Ligand-Linker Conjugates

• Type:

  Reference compound

• Related Pathways:

  PROTAC

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/brd4-ligand-linker-conjugate-1-tfa.html

• Purity:

  98.66

• Solubility:

  10 mM in DMSO|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  ClC1=CC=C(C2=NC3(CC3)C4=NN=C(C)N4C5=CC=C(C6=CN(CCCCCCN)N=C6)C=C25)C=C1.OC(C(F)(F)F)=O

• Molecular Weight:

  614.06

• References & Citations:

  [1]Sun D, et al. Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models. Mol Cancer Ther. 2021 Aug;20(8):1367-1377.|[2]Phillips AJ, et al. Preparation of bromodomain targeting degronimers for target protein degradation. World Intellectual Property Organization, WO2017197056 A1. 2017-11-16.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen, away from moisture)

• Clinical Information:

  No Development Reported